Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 91 points (-0.6%) at 15,838 as of Wednesday, Jan. 29, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 929 issues advancing vs. 2,026 declining with 145 unchanged. The Health Care sector currently sits down 0.5% versus the S&P 500, which is down 0.4%. Top gainers within the sector include Illumina ( ILMN), up 3.4%, Regeneron Pharmaceuticals ( REGN), up 2.2%, Teva Pharmaceutical Industries ( TEVA), up 2.1%, WellPoint ( WLP), up 2.3% and Vertex Pharmaceuticals ( VRTX), up 1.8%. On the negative front, top decliners within the sector include Bristol-Myers Squibb Company ( BMY), down 1.3%, Merck ( MRK), down 1.2%, Actavis ( ACT), down 0.9%, Covidien ( COV), down 0.9% and AstraZeneca ( AZN), down 0.7%. TheStreet would like to highlight 4 stocks pushing the sector higher today: 4. Medivation ( MDVN) is one of the companies pushing the Health Care sector higher today. As of noon trading, Medivation is up $9.22 (12.2%) to $85.00 on heavy volume. Thus far, 4.0 million shares of Medivation exchanged hands as compared to its average daily volume of 1.0 million shares. The stock has ranged in price between $82.60-$87.46 after having opened the day at $86.00 as compared to the previous trading day's close of $75.78. Medivation, Inc., a biopharmaceutical company, focuses on development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients. Medivation has a market cap of $5.5 billion and is part of the drugs industry. Shares are up 18.7% year-to-date as of the close of trading on Tuesday. Currently there are 10 analysts who rate Medivation a buy, no analysts rate it a sell, and 2 rate it a hold. TheStreet Ratings rates Medivation as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally high debt management risk. Get the full Medivation Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.